Loading organizations...
§ Private Profile · Hwaseodong, Kyonggi-do, South Korea
Develops novel antibody therapies, ADCs, using Stealth-Body technology for cancer, refractory diseases, immunotherapies.
CrossPoint Therapeutics is a Hwaseong-si, South Korea-based biotechnology company that develops novel antibody therapies and cancer immunotherapies utilizing proprietary Stealth-Body technology to reduce off-target toxicity. The seed-stage firm focuses on addressing refractory diseases through its antibody-drug conjugate platforms and specialized delivery solutions for proteins and small molecules, specifically targeting high unmet medical needs in the broader oncology sector. Operating with a seven-member team, the enterprise has raised $1.56 million in seed funding to advance its preclinical pipeline, which includes conducting primate studies to secure pre-IPO licensing agreements with global pharmaceutical corporations. The executive leadership includes Chief Technology Officer Kihwan Jang and leverages prior industry experience from prominent organizations such as LeadCompass Investment and the National Conference for New Drug Development to guide clinical strategy. CrossPoint Therapeutics was officially founded in October 2022 by Tae-Erk Kim.
CrossPoint Therapeutics has raised $1.6M across 1 funding round.
CrossPoint Therapeutics has raised $1.6M in total across 1 funding round.
CrossPoint Therapeutics has raised $1.6M across 1 funding round. Most recently, it raised $1.6M Seed in April 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2024 | $1.6M Seed | — | Infobank, Kite Foundation, Korea Omega Investment, Korea University Technology Holdings | Announced |
CrossPoint Therapeutics has raised $1.6M in total across 1 funding round.
CrossPoint Therapeutics's investors include Infobank, Kite Foundation, Korea Omega Investment, Korea University Technology Holdings.